Twist Bioscience (TWST) Operating Expenses (2017 - 2026)

Twist Bioscience (TWST) has reported Operating Expenses for 10 consecutive years, with $154.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Expenses rose 22.57% year-over-year to $154.7 million in Q2 2026; TTM through Jun 2026 was $576.8 million, a 14.29% increase from a year earlier, with the FY2025 full-year figure at $512.8 million, down 3.93% from the prior year.
• Operating Expenses was $154.7 million for Q2 2026 at Twist Bioscience, down from $156.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $170.4 million in Q2 2024 and troughed at $98.9 million in Q4 2022.
• A 5-year average of $127.6 million and a median of $123.8 million in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 57.39% in 2022 and decreased 25.95% in 2025, its largest moves.
• Over 5 years, Operating Expenses stood at $98.9 million in 2022, then rose by 19.83% to $118.5 million in 2023, then advanced by 4.12% to $123.4 million in 2024, then gained by 10.73% to $136.6 million in 2025, then gained by 13.22% to $154.7 million in 2026.
• The last three Operating Expenses figures came in at $154.7 million (Q2 2026), $156.6 million (Q1 2026), and $136.6 million (Q4 2025), per Business Quant data.